SenzaGen AB Company Description

SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity.

The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; GARD air: respiratory sensitization assessment, and the GARD® technology.

It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, skin sensitization medical device services; tailored advisory services for medical devices; and substance based medical devices.

In addition, the company offers regulatory toxicity testing services including skin corrosion, skin irritation, skin sensitization, and skin absorption; eye irritation testing services; phototoxicity testing services; and genotoxicity testing services.

Further, it provides advisory services, such as pharma, medical devices, cosmetics, and chemical; and area of expertise, and the expert team services.

The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization.

The company was incorporated in 2010 and is headquartered in Lund, Sweden.

SenzaGen AB

Country	Sweden
Founded	2010
Industry	Diagnostics & Research
Sector	Healthcare
Employees	34
CEO	Peter Nahlstedt

Contact Details

Address: Building 401 Lund, 223 81 Sweden
Phone	46 4 62 75 62 00
Website	senzagen.com

Stock Details

Ticker Symbol	SENZA
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0010219626
SIC Code	2836

Key Executives

Name	Position
Peter Nahlstedt	President and Chief Executive Officer
Marianne Olsson	Vice President of Finance
Dr. Henrik Johansson	Chief Scientist
Tina Dackemark Lawesson	Vice President of Marketing and Communications
Andy Forreryd	Vice President of Sales
Helen Olsson	Vice President of Human Resources